Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03973281

EASE: The Materna Prep Pivotal Study

This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery.

Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device

Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor.

Subject participation in the study is targeted to be 12 months from the time of the use of the device during delivery.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Alabama at Birmingham, Birmingham, Alabama, United States

Loading trial locations.

About this study

Vaginal delivery is a major risk factor for pelvic floor dysfunction. Clinical aspects of pelvic floor dysfunction include pelvic organ prolapse, sexual dysfunction, and fecal and urinary incontinence. Trauma to the pelvic structures occurs as the fetal head passes through the vaginal canal, especially with acute distension at the time of crowning - the exiting of the fetal head.

The Materna Prep Device is a single-use, semi-automated dilator used during the first phase of labor in order to prepare the vaginal canal for vaginal delivery. By slowly pre-stretching the vagina and surrounding pelvic tissues during labor, the device is essentially dictating the strain rate of the tissue during labor. In previous feasibility studies, the elastic recovery of the tissue has been shown to be on the order of several hours, allowing the benefits of pre-stretching the vagina and surrounding pelvic tissues to last throughout labor. The device is intended to be removed prior to the initiation of the second stage of labor, for delivery to occur unobstructed.

The target patient population for this study is nulliparous women entering the first phase of labor and scheduled for vaginal delivery with an epidural.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Criteria for inclusion

  • Subject is scheduled for vaginal birth.
  • Subject is gestating a single fetus.
  • Subject is nulliparous, or had a previous pregnancy terminated within 24 weeks gestation.
  • Subject is able and willing to comply with the protocol required follow-up visits.
  • Subject is able and willing to provide written informed consent prior to enrollment.
  • In the opinion of the Investigator, the subject has sufficient mental capacity to understand the informed consent form (ICF), comply with the protocol requirements, and provide clinically relevant and reliable feedback regarding their experience with the device.
  • Subject receives epidural anesthesia during labor prior to enrollment.
  • Subject is 18 years of age or older at time of consent.

Exclusion criteria

Criteria for exclusion

  • Subject has high likelihood of less than 1 hour of potential device dilation time after she arrives at the hospital.
  • Subject is planning or requires a Caesarean-section prior to randomization.
  • Subject begins labor with less than 36 weeks gestation.
  • Subject has a neurological disorder that could cause pelvic floor dysfunction, such as multiple sclerosis or spinal cord injury.
  • Subject has a collagen-associated disorder that affects tissue elasticity, such as scleroderma or Ehlers-Danlos syndrome.
  • Subject has a localized (genital tract) or systemic infection.
  • Subject has a medical history which could lead to pelvic floor dysfunction, such as prior pelvic fractures, pelvic soft tissue injuries, or vaginal surgery.
  • Subject has any general health condition or systemic disease that may represent, in the opinion of the Investigator, a potential increased risk associated with device use or pregnancy.
  • Subject has placenta previa or vasa previa.
  • Subject has known significant chromosomal or structural fetal anomalies.
  • Subject has a category 2 and/or 3 fetal tracing that is unresolved.
  • Subject is observed to have friable, denuded, or markedly edematous vaginal tissue during the course of labor.

Treatment and study plan

Materna Prep Device

Device

Materna Prep Device

Standard of Care (SOC)

Other

Standard of Care (SOC)

Primary outcomes

  1. The occurrence of pelvic muscle injury, defined as complete detachment of the levator ani muscle diagnosed via ultrasound imaging

    Time frame: 3-month Follow-up

    Use transperineal ultrasound to identify levator ani muscle detachment

  2. The occurrence of pelvic muscle injury, defined as complete detachment of the levator ani muscle diagnosed via ultrasound imaging

    Time frame: 12-month Follow-up

    Use transperineal ultrasound to identify levator ani muscle detachment

Secondary outcomes

  1. The occurrence of pelvic muscle injury, defined as complete or partial detachment of the levator ani muscle diagnosed via ultrasound imaging

    Time frame: 3-Month Follow-up

    Use transperineal ultrasound to identify levator ani muscle detachments

  2. The occurrence of pelvic muscle injury, defined as complete or partial detachment of the levator ani muscle diagnosed via ultrasound imaging

    Time frame: 12-Month Follow-up

    Use transperineal ultrasound to identify levator ani muscle detachments

  3. Length of 2nd Stage Labor

    Time frame: Intra-Procedure

    Compare the length of the second stage of labor, defined as the time from the cervix being dilated to 10 cm to the complete delivery of the baby between study groups.

  4. Levator Hiatal Area

    Time frame: 3-month and 12-month Follow-up

    Compare the levator hiatal area (cm2 - measurement between pelvic muscle and pelvic bone)

  5. Perineal Lacerations

    Time frame: Intra-Procedure

    Compare the rate of perineal lacerations determined by visual insepction post-delivery between study groups

  6. Obstetric anal sphincter injury - OASI

    Time frame: Intra-Procedure

    Compare the rate of tearing of the muscles of the anal sphincter between study groups.

  7. Obstetric anal sphincter injury - OASI

    Time frame: 3-month follow-up

    Compare the rate of tearing of the muscles of the anal sphincter on ultrasound between study groups.

  8. C-Sections

    Time frame: Intra-Procedure

    Compare the rate of C-Section due to arrest of labot in the second stage

  9. Infant APGAR scores

    Time frame: Intra-Procedure

    Compare infant APGAR scores between study groups. A score of 7-10 after 5 minutes is reassuring, a score of 4-6 after minutes is moderately abnormal and a score of 0-3 is concerning.

  10. Qualitative pelvic health feedback

    Time frame: 3-Month and 12-month Follow-up

    Compare qualitative pelvic health feedback assessed by PFIQ-7 (utilizing 4-point scale representing "Not at all" to "quite a bit") questionnaires from subjects between study groups.

  11. Qualitative pelvic health feedback

    Time frame: 3-Month and 12-month Follow-up

    Compare qualitative pelvic health feedback assessed by PFID-20 (Utilizing a 5 point scale with 0=not present to 4=quite a bit) questionnaires from subjects between study groups.

  12. Qualitative pain

    Time frame: 3-Month and12-month Follow-up

    Compare qualitative pain assessed by VAS (0-10, with 0 being No pain and 10 being severe pain) from subjects between study groups

  13. User Satifaction

    Time frame: Intra-Procedure

    Satisfaction assessed by a clinician satisfaction questionnaire after device use.

  14. Operative Delivery

    Time frame: Intra-Procedure

    Compare the rate of instrument use in vaginal deliveries between study gorups

  15. Types of Perineal Lacerations

    Time frame: Intra-Procedure

    Compare rate of the TYPES of perineal lacerations between study groups.

  16. Reasons for C-Sections

    Time frame: Intra-Procedure

    Compare incidence of the REASONS for C-Sections between study groups

  17. First Push to Delivery

    Time frame: Intra-Procedure

    Compare the mean time form first push to delivery between study groups.

Sponsors and collaborators

Lead sponsor

Materna Medical

Industry

Collaborators

  • University of Michigan

Registry information

Official study title

A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of the Materna Prep Device to Pre-stretch the Vaginal Canal and Pelvic Floor Tissues in Preparation for Vaginal Delivery

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Jun 4, 2019
Registry last updated
Sep 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.